The Oncologist
The official journal of the Society for Translational Oncology

Supplemental Table for:
Abnormal pre-treatment liver function tests are associated with discontinuation of PRRT in a U.S.-based neuroendocrine tumor cohort
Bryson Katona et al.

Supplemental Table 1: Adverse effects observed with PRRT (N = 149 sessions)

Adverse effect during infusion	Occurrences
Nausea	21 (14%)
Vomiting	3 (2%)
Hemodynamic change	2 (1%)
Dizziness	1 (1%)
Flushing	2 (1%)
Adverse effect between PRRT sessions	
Fatigue	64 (43%)
Nausea	28 (19%)
Increase in carcinoid-syndrome related symptoms	20 (13%)
Vomiting	6 (4%)
Abdominal pain	12 (8%)
Body pain	8 (5%)
Loss of appetite	11 (7%)
Mood disorder	5 (3%)
Dizziness	3 (2%)
Increased edema/ascites	7 (4%)
Hair loss	3 (2%)
Small bowel obstruction	1 (1%)